The transactions highlighted below are representative of Greenhill engagements. In addition, the Firm has completed many engagements that were not publicly-disclosed.
Recent Transactions
Sort By
20-Oct-05
$NA
Target:
Drakkar Holdings SA (Adisseo Group)
Acquiror:
China National Chemical Corporation
Advised CVC Capital Partners on the divestiture of Adisseo via the sale of Drakkar Holdings SA to China National BlueStar, a subsidiary of state-owned diversified chemicals company China National Chemical Corporation. Adisseo is a leading player in the animal nutrition market
28-Nov-05
$103 million
Target:
Akzo Nobel N.V.
Acquiror:
Hexion Specialty Chemicals Inc.
(Ink and Adhesive Resins business) Advised Akzo Nobel N.V., a global leader in coatings, chemicals and healthcare on the sale of its Ink and Adhesive Resins business to Hexion Specialty Chemicals Inc
20-Feb-06
$254 million
Target:
Textile Effects
Acquiror:
Huntsman Corporation
(division of Ciba Specialty Chemicals AG)
Advised Ciba Specialty Chemicals AG on the sale of its global Textile Effects business
24-Mar-06
$21.2 billion
Target:
Schering AG
Acquiror:
Bayer AG
Advised Bayer on its public offer for Schering, an international pharmaceuticals group based in Berlin, Germany
03-May-07
$8.5 billion
Target:
IPSCO Inc.
Acquiror:
SSAB Svenskt Stål AB
Acted as lead financial advisor to SSAB Svenskt Stål AB on its acquisition of IPSCO Inc., a leading Canadian producer of energy tubulars and steel plate in North America with an annual steel making capacity of 4.3 million tons
31-Jul-07
$491 million
Target:
DEUTZ Power Systems
Acquiror:
3i
Sole advisor to DEUTZ AG on the divestiture of its division DEUTZ Power Systems, a leading manufacturer of gas fired engines for decentralized power generation
22-Jan-08
$3.4 billion
Target:
Ventana Medical Systems, Inc.
Acquiror:
Roche Holding Ltd.
Advised Roche Holding Ltd., a world-leading provider of healthcare pharmaceuticals and diagnostics, on its acquisition of Ventana Medical Systems, Inc., a US based provider of histopathology diagnostic equipment
08-Oct-08
$NA
Target:
MAN Ferrostaal AG
Acquiror:
International Petroleum Investment Company (IPIC)
Advised MAN AG in relation to its 70% sale of MAN Ferrostaal AG, a worldwide supplier of industrial services for the construction of large-scale industrial plants and machine supply, to International Petroleum Investment Company (IPIC)
12-Oct-08
$6.0 billion
Target:
Hapag-Lloyd AG
Acquiror:
Albert Ballin KG
Advised TUI AG, Europe’s largest tourism company, on its sale of its shipping division Hapag-Lloyd AG, one of the leading global container shipping companies
12-Mar-09
$46.9 billion
Target:
Genentech, Inc.
Acquiror:
Roche Holding Ltd.
Advised Roche Holding Ltd., a world-leading provider of healthcare pharmaceuticals and diagnostics, on its acquisition of the outstanding publicly held interest in Genentech, Inc., a leading biotechnology company
09-Nov-09
$327 million
Target:
Enzon Pharmaceuticals, Inc.
Acquiror:
Sigma-Tau Pharmaceuticals
Advised Enzon Pharmaceuticals, Inc., a biopharmaceutical company on the sale of its specialty pharmaceutical business to Sigma-Tau, an Italian pharmaceutical company
16-Sep-10
$NA
Target:
KemFine UK Ltd
Acquiror:
AURELIUS AG
Advised KemFine Group Oy, a 3i portfolio company, on the sale of its UK-based fine chemicals business, KemFine UK Ltd, to AURELIUS AG
01-Dec-10
$100 million
Target:
Clyde Process Solutions plc
Acquiror:
S-Process Equipment International S.à r.l. (Schenck Process)
Advised S-Process Equipment International S.à r.l. (“Schenck Process”), a global leader in bulk material handling, providing applications incorporating weighing, feeding, screening and automation solutions, on its acquisition of Clyde Process Solutions plc, a global provider of pneumatic conveying and air filtration solutions for process industries
15-Dec-10
$12.9 billion
Target:
Alcon, Inc.
Acquiror:
Novartis AG
Advised the Independent Director Committee of Alcon, Inc., an ophthalmic pharmaceutical company, on the sale of Alcon’s outstanding publicly held interest to Novartis AG, a global pharmaceutical company
15-Jan-11
$105 million
Target:
telerob Holding GmbH
Acquiror:
Cobham plc
Advised the shareholders of telerob Holding GmbH, a German-based market leader in the development and manufacture of advanced bomb disposal robots and integrated threat response vehicles, on the sale of the Company to Cobham plc, the UK-based, internationally operating aerospace, defence and security technology group
22-Jun-11
$NA
Target:
KemFine Group Oy
Acquiror:
CABB AG
Advised 3i on the disposal of KemFine Group Oy, a leading custom manufacturer of fine chemicals, to CABB AG
01-Mar-12
$NA
Target:
Minority stake in Stadler Rail
Acquiror:
Peter Spuhler
Advised Capvis, one of the leading buyout firms in Switzerland and one of the main mid-market private equity firms in German-speaking Europe, on the staged exit from of its 20% minority stake in Stadler Rail, by selling to Peter Spuhler, CEO and majority shareholder in Stadler Rail
26-Mar-12
$513 million
Target:
ISTA Pharmaceuticals, Inc.
Acquiror:
Bausch + Lomb, Inc.
Advised ISTA Pharmaceuticals, an ophthalmic pharmaceutical company, on its sale to Bausch + Lomb, Inc., a global ophthalmic products company
20-Sep-12
$1.0 billion
Target:
Becker Underwood
Acquiror:
BASF
Advised Norwest Equity Partners on the sale of its portfolio company Becker Underwood, a global leader in the development and commercialization of yield-improving seed-applied biological products for the Agricultural market, to BASF, the world’s largest chemical company
21-Dec-12
$75 million
Target:
Australian Portable Buildings
Acquiror:
Black Diamond Group Limited and WEQ Britco LP
Advised CHAMP Ventures on the sale of its portfolio company Australian Portable Buildings, a leading Australian manufacturer of customized modular buildings, to a consortium comprising Black Diamond Group and WEQ Britco
20-May-13
$8.5 billion
Target:
Warner Chilcott, plc
Acquiror:
Actavis, Inc.
Advised Actavis, Inc., a global, integrated specialty pharmaceutical company focused on developing, manufacturing and distributing generic, branded and biosimilar products on its acquisition of Warner Chilcott plc
15-Oct-13
$64 million
Target:
Detergents & Intermediates Business Unit of Clariant International Ltd
Acquiror:
International Chemical Investors Group
Advised Clariant International Ltd, the Swiss specialty chemicals company, on the sale of its Detergents & Intermediates Business Unit to International Chemical Investors Group, a privately owned industrial holding company focusing on mid-sized chemicals and pharmaceutical businesses
30-Oct-13
$NA
Target:
Leather Services Business Unit of Clariant International Ltd
Acquiror:
Stahl Holdings
Advised Clariant International Ltd, the Swiss specialty chemicals company, on the sale of its Leather Services Business Unit to Stahl Holdings (portfolio company of Wendel), a leading supplier in the leather chemicals and performance coating industries
18-Feb-14
$25.1 billion
Target:
Forest Laboratories Inc.
Acquiror:
Actavis plc
Advised Actavis plc, a global, integrated specialty pharmaceutical company focused on developing, manufacturing and distributing generic, brand and biosimilar products on its acquisition of Forest Laboratories Inc.
10-Apr-14
$NA
Target:
Flint Group
Acquiror:
Consortium of Goldman Sachs MBD and Koch Industries
Advised Flint Group, a portfolio company of CVC Capital Partners and a global leader in the manufacturing of printing inks and consumables on its sale to a consortium consisting of Goldman Sachs Merchant Banking and the private equity arm of Koch Industries